North America Cardiac Surgery Devices Market

North America Cardiac Surgery Devices Market Size

The size of the North America cardiac surgery devices market was worth USD 0.70 billion in 2024. The North America market is anticipated to grow at a CAGR of 3.12% from 2025 to 2033 and be worth USD 0.92 billion by 2033 from USD 0.72 billion in 2025.

MARKET DRIVERS

Aging Population and Technological Advancements in Cardiac Surgery Devices

Increasing investments by the governments of North American countries to improve healthcare and R&D of healthcare in this region are expected to drive market growth during the forecast period.

The rising older population suffering from cardiovascular diseases in this region significantly contributes to the market growth. An estimated 43.7 million people suffered from cardiovascular disorders that are aged 60 years and above in the U.S., according to the evaluation of the American Heart Association. Moreover, 69.1% of men and 97.9% of women between 60 and 79 years of age had suffered from cardiac disorders in 2015 in the U.S. Around 68% of increasing in hospitals across all age groups, as per the data submitted by Heart & Stroke’s analysis of Canadian hospitalization during 2024-2029. For example, Medtronic has introduced its minimally invasive cardiac surgery products in the U.S. over an elegant distribution agreement with Miami Instruments LLC.

MARKET RESTRAINTS

High Costs, Limited Awareness, and Shortage of Skilled Surgeons

This technology will continue to strengthen advancements towards the cardiac surgery devices market in the future. The deficit of awareness in people and scarcity of expert professionals are restraining the growth in the region. Extortionate investments in cost and shortage of experienced surgeons are hindering the growth in the area.

GEOGRAPHICAL ANALYSIS

North America had the largest market for cardiac surgery devices globally by share in 2024, owing to the growing geriatric population and rising incidence of heart diseases due to unhealthy eating habits. In the North America region, the United States has the largest market share. Factors such as the growing prevalence of heart diseases and rising healthcare expenditure are expected to drive market growth during the forecast period.

The U.S. is ruling the market because of the increase in regular circulatory system disorders and increasing spending on healthcare.

Increasing patient count and growing awareness programs, and escalating funds and investments for research schemes are predicted to surge North America's market growth. The unhealthy and stressful lifestyle of consumers, over-weight related issues, and latest technologies in the market, and growing requirement for heart surgeries in developed and undeveloped countries of the region are anticipated to present growth opportunities for the market.

The Canadian market is right behind the U.S. in leading the cardiac surgery devices market because of the growing stress of cardiovascular diseases and rising assumption of minimally invasive procedures. Every year 62,000 people are attacked with stroke in this Canada and are also anticipated to grow, and more than 405,000 people in this country live with the effects of stroke. Spending on healthcare shows considerable growth in both developed and existing economies, and growing life duration integrated with stress in modern-day life makes old people patients demand more trendsetters.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Cardiac Surgery Devices Market profiled in this report are Trinity Biotech, Abiomed, Inc., Cardinal Health, C. R. Bard, Inc., MedWaves Incorporated, CyberHeart Incorporated, and Transmedics, Inc., among others.

MARKET SEGMENTATION

This research report on the North America cardiac surgery devices market is segmented and sub-segmented into the following categories.

By Product Type

• Cardiopulmonary Bypass Equipment
• Beating Heart Surgery Systems
• Perfusion Disposables
• Cardiac Ablation Devices

By Application

• Cardiac Arrhythmia
• Coronary Heart Disease
• Congenital Heart Defects
• Congestive Heart Failure
• Other Applications

By Age Group

• New-born (0-30 Days)
• Infant (31 Days-1 Year)
• Children (1-18 Years)
• Adult (18+ Years)

By Country

• United States
• Canada
• Mexico
• Rest of North America